
Experts say eating MORE of an ultra-processed food is actually good for you
But not all ultra-processed foods are created equal.
Health experts are urging Americans to give faux meat a chance, citing lower risks of heart disease and a better carbon footprint.
Plant-forward diets, including the doctor-endorsed Mediterranean diet, are lauded for their inclusion of clean protein like nuts and legumes, mineral-rich leafy greens, and fibrous whole grains.
But doctors have been hesitant to recommend meat-alternative brands like Beyond Meat and Impossible Burgers because of the processing used to create them.
Meat substitutes may undergo various temperature treatments or 3D printing to mimic the texture of real meat, and may contain binders, emulsifiers, dyes, flavorings, stabilizers, and preservatives.
Despite this, doctors and nutritionists encourage their patients to make the switch to plant-based alternatives, which contain the same amount of protein, less saturated fat, fiber, and other beneficial vitamins.
Plant-based meat companies have a vested interest in appealing to carnivores who are concerned about the additives in everyday foods, including followers of the Make America Healthy Again movement.
Companies have overhauled some of their recipes amid flagging sales, lowering saturated fat and sodium, to bring them in.
A 2024 analysis published in the Canadian Journal of Cardiology of dozens of studies found that compared with meat, plant-based alternatives, while considered ultraprocessed, are generally healthier than meat.
They contain less saturated fat and cholesterol and have more fiber, showing in clinical trials to confer lower bad cholesterol and reduced body weight.
'Doctors and dietitians are reluctant to consider alternative proteins when advising patients on nutrition because they view these foods as ultra-processed,' nutrition scientist Roberta Alessandrini, director of the Dietary Guidelines Initiative at PAN International, told CNN.
'Yet if carefully chosen, these foods can be a valid and helpful way to shift toward more plant-forward diets, which are good for people and the planet.'
Plant-based burgers generally have their basis in soy , pea, or rice proteins, coconut oil, potato protein, yeast to impart a meaty taste.
They also contain compounds to bind the 'meat' together, such as methylcellulose, which gives the burgers fiber and, in some cases beet juice extract to simulate blood.
Despite being nutrient dense and overall beneficial, meat-free alternatives come from highly synthesized ingredients like soy protein concentrate, processed fats like coconut oil, binders and texturizers to better resemble meat, and the addition of non-whole food-based nutrients like B12 and zinc.
An ultraprocessed plant-based burger is a far cry from an ultraprocessed Twinkie or hot dog, though.
Ultraprocessed junk foods have strong links to obesity, heart disease, and diabetes, all while packing little to no nutritional benefits. No such links have been established with meat-free alternatives.
An 85 percent lean ground beef burger contains around 6.5 grams of saturated fat, compared to six grams in an Impossible Burger and two grams in a Beyond Burger.
They all contain similar amounts of protein, ranging from 19 to 21 grams per serving.
The high sodium content of meat alternatives is a significant downside. A 2019 CNN analysis found that Beyond, Impossible, and more traditional grain-based burgers each contained 370 to 390 milligrams of sodium.
Store-bought turkey burgers, however, contained 95 to 115 milligrams of sodium, while beef patties had only 65 to 75 milligrams.
They caution that this might be a misleading comparison, given that many people salt and season their meat as they cook it.
Processed and red meats are fine to eat sparingly, but eating them every day or even several times a week has been linked to colorectal and breast cancers, heart disease, and diabetes, though evidence is limited.
Concerns over health and nutrition are the primary drivers of the shift toward plant-based meat, although many people opt for non-meat alternatives due to concerns related to climate change.
Global meat production is a significant contributor to climate change, and demand is projected to increase by at least 50 percent by 2050.
Still, most people begin to incorporate meatless alternatives into their diet due to concerns about their weight, cholesterol, blood pressure or other health-related red flags.
'The fat composition of beef is so undesirable for health that it's very easy to be better than that,' Dr Walter Willett, professor of epidemiology and nutrition at Harvard, said.
'Animal products not only have too much saturated fat but lack polyunsaturated fat, fiber, and many of the minerals and vitamins available in plants.'
Those minerals and vitamins, such as B12, can be added to meatless alternatives in a similar way to how producers add vitamins D and A to milk.
Ultra-processed junk foods have strong links to obesity, heart disease, and diabetes, all while packing little to no nutritional benefits.
Plant-based meats are nutrient-dense, though, more so resembling a can of beans.
'So I think we really need to look at each one of these novel products on its own merits,' Dr Willett said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
5 minutes ago
- The Independent
WeightWatchers boss says ‘exciting work to do' amid impact of weight loss jabs
WeightWatchers was slower to adapt to the emergence of anti-obesity jabs than rivals, its boss has admitted, as the 62-year-old brand strives to catch up with rapidly evolving attitudes towards weight loss. Tara Comonte, chief executive of the US-based business, said it had a lot of work to do after going through a 'reset'. WeightWatchers recently announced it had emerged from bankruptcy after writing off a portion of the 1.15 billion US dollar (£860 million) debt on its balance sheet. It came as the business was competing with the emergence of GLP-1s – the scientific term for weight loss jabs, which work by reducing food cravings – and a new wave of apps and advice spreading on social media. Ms Comonte told the PA news agency that it 'wasn't as quick to medical weight loss solutions' as some other firms in the US, notably so-called 'telehealth' businesses that offer healthcare remotely. WeightWatchers, which runs some 20,000 workshops each month globally, is now 'at the beginning of the journey' towards forging a new place in the industry and meeting demand from current and future members, Ms Comonte said. 'This whole industry is going through somewhat of a reset and we have exciting work to do,' she told the PA news agency. 'This is a moment where, possibly more than ever before, people are talking about weight, and weight health… where people are seeking more education than ever before, and there are more voices than ever before.' Ms Comonte said the brand was known for 'trust and science' and it was important to harness that 'as there are more and more voices in the ecosystem'. WeightWatchers recently partnered with anti-obesity drugs provider CheqUp in the UK so patients taking the medication can access its 'companion' diet and lifestyle support app. It forms part of its efforts to muscle into the market by offering behavioural strategies and community-based support to people using or coming off the medication. 'There's no 'us and them' anymore,' Ms Comonte told PA, hitting back at weight loss jabs often being pitted as rivals to its model. Dr Kim Boyde, WeightWatchers' newly appointed chief medical officer, said not all its members will want or need weight loss medication – but stressed that it was 'imperative' the programme offers it to those that might benefit. Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs. Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects.


Reuters
an hour ago
- Reuters
Roche to investigate whether new drug can delay or prevent Alzheimer's disease
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, it said on Sunday, as a part of the company's growing development programme for the disease. The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement. Trontinemab is designed so that the drug is transported across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain — in hopes of delivering more of the treatment to the brain. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the U.S. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.


Reuters
3 hours ago
- Reuters
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday. The new late-stage study will target people who are at risk of cognitive decline and aim to slow down the emergence of symptoms or prevent them fully, the report said, citing a statement. The new pre-clinical study is the third largest late-stage trial that the company has announced for its drug trontinemab, which uses an experimental technology called brain shuttle to ferry medicine past the protective blood-brain barrier, according to the report. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently with Lilly's Alzheimer's drug Kisunla getting recommendation from the European Medicines Agency (EMA) last week. Reuters could not immediately verify the report. Roche did not immediately respond to a request for a comment. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi, and Eli Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They also carry hefty price tags and the risk of serious brain swelling and bleeding.